Easywell Biomedicals, Inc.(TW:1799)
NT$25.10+0.20 (+1.41%)
TW:1799
Easywell Biomedicals, Inc. financials statements
NT$25.10
At close:+0.20 (+1.41%)
Easywell Biomedicals, Inc. (1799) Ratios
Easywell Biomedicals, Inc. Ratios
TW:1799's free cash flow for Q2 2026 was NT$23.91M. For the 2026 fiscal year, TW:1799's free cash flow was decreased by NT$-3.89M and operating cash flow was NT$27.80M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.52 | 1.93 | 3.98 | 6.43 | 14.10 |
| Quick Ratio | 1.95 | 1.32 | 3.65 | 6.01 | 13.53 |
| Cash Ratio | 1.01 | 0.77 | 2.06 | 2.48 | 4.23 |
| Solvency Ratio | 0.03 | -0.02 | -0.14 | -0.23 | -0.23 |
| Operating Cash Flow Ratio | 0.45 | -0.38 | -1.19 | -0.83 | -3.55 |
| Short-Term Operating Cash Flow Coverage | 1.39 | -0.79 | -3.50 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ 110.27M | NT$ 52.03M | NT$ -82.35M | NT$ 9.85M | NT$ 158.27M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.33 | 0.37 | 0.32 | 0.30 | 0.26 |
| Debt-to-Equity Ratio | 0.62 | 0.79 | 0.63 | 0.47 | 0.37 |
| Debt-to-Capital Ratio | 0.38 | 0.44 | 0.39 | 0.32 | 0.27 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.87 | 2.09 | 1.98 | 1.59 | 1.45 |
| Debt Service Coverage Ratio | 0.21 | 0.06 | -1.37 | -4.91 | -5.20 |
| Interest Coverage Ratio | -2.99 | -3.30 | -8.45 | -8.76 | -9.55 |
| Debt to Market Cap | 0.02 | 0.03 | 0.01 | 0.00 | 0.00 |
| Interest Debt Per Share | 3.62 | 4.87 | 3.54 | 3.18 | 3.28 |
| Net Debt to EBITDA | 6.05 | 18.71 | -1.44 | -2.26 | -2.09 |
| Profitability Margins | |||||
| Gross Profit Margin | 41.13% | 55.40% | 62.85% | 42.66% | 25.56% |
| EBIT Margin | -11.25% | -12.42% | -55.46% | -84.42% | -77.85% |
| EBITDA Margin | 4.01% | 2.36% | -31.48% | -47.22% | -41.92% |
| Operating Profit Margin | -11.25% | -12.92% | -59.91% | -84.42% | -77.85% |
| Pretax Profit Margin | -12.58% | -16.34% | -62.55% | -94.06% | -86.00% |
| Net Profit Margin | -12.24% | -18.04% | -53.31% | -90.00% | -76.23% |
| Continuous Operations Profit Margin | -12.63% | -16.37% | -62.65% | -94.13% | -86.43% |
| Net Income Per EBT | 97.29% | 110.40% | 85.23% | 95.68% | 88.64% |
| EBT Per EBIT | 111.87% | 126.46% | 104.41% | 111.42% | 110.47% |
| Return on Assets (ROA) | -5.66% | -6.47% | -11.93% | -13.72% | -11.90% |
| Return on Equity (ROE) | -10.59% | -13.56% | -23.63% | -21.80% | -17.21% |
| Return on Capital Employed (ROCE) | -6.63% | -6.45% | -14.98% | -13.62% | -12.51% |
| Return on Invested Capital (ROIC) | -5.95% | -5.36% | -14.25% | -13.48% | -12.41% |
| Return on Tangible Assets | -6.14% | -7.12% | -13.69% | -16.02% | -13.87% |
| Earnings Yield | -1.65% | -1.26% | -3.14% | -8.77% | -6.43% |
| Efficiency Ratios | |||||
| Receivables Turnover | 9.05 | 9.32 | 3.98 | 8.74 | 6.45 |
| Payables Turnover | 42.78 | 5.28 | 10.71 | 43.56 | 313.78 |
| Inventory Turnover | 2.22 | 0.93 | 2.39 | 3.82 | 7.15 |
| Fixed Asset Turnover | 1.22 | 0.98 | 0.50 | 0.31 | 0.35 |
| Asset Turnover | 0.46 | 0.36 | 0.22 | 0.15 | 0.16 |
| Working Capital Turnover Ratio | 1.46 | 1.40 | 0.75 | 0.44 | 0.54 |
| Cash Conversion Cycle | 196.33 | 362.62 | 210.26 | 128.85 | 106.49 |
| Days of Sales Outstanding | 40.33 | 39.14 | 91.79 | 41.78 | 56.59 |
| Days of Inventory Outstanding | 164.53 | 392.58 | 152.54 | 95.45 | 51.07 |
| Days of Payables Outstanding | 8.53 | 69.10 | 34.07 | 8.38 | 1.16 |
| Operating Cycle | 204.86 | 431.73 | 244.33 | 137.23 | 107.65 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.01 | -1.32 | -1.32 | -0.46 | -1.23 |
| Free Cash Flow Per Share | 0.88 | -1.43 | -1.49 | -0.53 | -1.31 |
| Dividend Paid and CapEx Coverage Ratio | 8.10 | -12.47 | -8.16 | -7.14 | -16.64 |
| Capital Expenditure Coverage Ratio | 8.10 | -12.47 | -8.16 | -7.14 | -16.64 |
| Operating Cash Flow Coverage Ratio | 0.29 | -0.28 | -0.39 | -0.15 | -0.39 |
| Operating Cash Flow to Sales Ratio | 0.21 | -0.29 | -0.56 | -0.30 | -0.65 |
| Free Cash Flow Yield | 2.46% | -2.22% | -3.68% | -3.32% | -5.81% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -60.68 | -79.38 | -31.78 | -11.42 | -15.60 |
| Price-to-Sales (P/S) Ratio | 7.43 | 14.30 | 17.00 | 10.26 | 11.86 |
| Price-to-Book (P/B) Ratio | 6.43 | 10.75 | 7.54 | 2.49 | 2.68 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 40.58 | -44.98 | -27.17 | -30.10 | -17.20 |
| Price-to-Operating Cash Flow Ratio | 35.57 | -48.59 | -30.49 | -34.32 | -18.23 |
| Price-to-Earnings Growth (PEG) Ratio | 2.23 | 2.19 | 3.68 | 3.29 | 0.72 |
| Enterprise Value Multiple | 191.52 | 624.66 | -55.46 | -23.99 | -30.38 |
| Enterprise Value | 4.58B | 7.97B | 4.74B | 2.03B | 2.51B |
| EV to EBITDA | 191.52 | 624.66 | -55.46 | -23.99 | -30.38 |
| EV to Sales | 7.67 | 14.74 | 17.46 | 11.33 | 12.73 |
| EV to Free Cash Flow | 41.90 | -46.37 | -27.89 | -33.23 | -18.47 |
| EV to Operating Cash Flow | 36.73 | -50.09 | -31.31 | -37.89 | -19.58 |
| Tangible Book Value Per Share | 4.85 | 5.01 | 4.09 | 6.49 | 8.47 |
| Shareholders’ Equity Per Share | 5.57 | 5.98 | 5.36 | 6.39 | 8.39 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 |
| Revenue Per Share | 4.82 | 4.50 | 2.37 | 1.55 | 1.89 |
| Net Income Per Share | -0.59 | -0.81 | -1.27 | -1.39 | -1.44 |
| Tax Burden | 0.97 | 1.10 | 0.85 | 0.96 | 0.89 |
| Interest Burden | 1.12 | 1.32 | 1.13 | 1.11 | 1.10 |
| Research & Development to Revenue | 0.38 | 0.51 | 1.00 | 1.17 | 1.21 |
| SG&A to Revenue | 0.19 | 0.18 | 0.23 | 0.16 | 0.12 |
| Stock-Based Compensation to Revenue | 0.01 | 0.02 | 0.06 | 0.00 | 0.00 |
| Income Quality | -1.66 | 1.80 | 0.89 | 0.32 | 0.76 |
Currency in TWD
